In human prostate tumors, FOXP1 loss added to PTEN loss correlates with significantly higher levels of androgen-responsive signature gene expression than the repressed levels caused by PTEN loss alone, but shows no significant difference in androgen-responsive signature expression compared to tumors without loss or with only FOXP1 loss alone (Fig. 3d, Supplementary Fig. 6c). This evidence concerns the gene FOXP1 and prostate neoplasm.